VYGR

SEC source: 0001104659-22-005021 · tm223208-2_4seq1.xml · nonDerivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director · Interim CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,300

F1 · shares: Consists of shares of common stock issuable under an aggregate of 26,300 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. 100% of the shares of common stock underlying the RSU award vest on the six-month anniversary of such vesting commencement date, subject to the Reporting Person's continued service as a director, officer, or otherwise.

SEC source: 0001104659-22-005020 · tm223208-4_4seq1.xml · derivative · entry 2

Higgins Michael J · CIK 0001478521 · Director · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 161,000

Underlying: Common Stock · 161,000 shares

Expires 2032-01-13

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. 1/5th of the shares of common stock underlying the option vest on each of February 12, 2022, March 12, 2022, April 12, 2022, May 12, 2022 and June 2, 2022, subject to the Reporting Person's continued service as an interim executive officer.

SEC source: 0001104659-22-005020 · tm223208-4_4seq1.xml · nonDerivative · entry 1

Higgins Michael J · CIK 0001478521 · Director · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,205

F1 · shares: Consists of shares of common stock issuable under an aggregate of 45,205 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, January 13, 2022. 100% of the shares of common stock underlying the RSU award vest on the six-month anniversary of such vesting commencement date, subject to the Reporting Person's continued service as a director, officer, or otherwise.

SEC source: 0001104659-22-004515 · tm223086-1_4seq1.xml · nonDerivative · entry 3

Burek Julie · CIK 0001894915 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,257

F2 · kind: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.92 to $3.22, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.

SEC source: 0001104659-22-004515 · tm223086-1_4seq1.xml · nonDerivative · entry 2

Burek Julie · CIK 0001894915 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,522

SEC source: 0001104659-22-004515 · tm223086-1_4seq1.xml · nonDerivative · entry 1

Burek Julie · CIK 0001894915 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,585

F1 · kind: Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).

F1 · shares: Represents shares acquired under the Voyager Therapeutics, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(c) and Rule 16b-3(d).

SEC source: 0001104659-21-144995 · tm2134192-2_4seq1.xml · derivative · entry 2

Burek Julie · CIK 0001894915 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2031-11-26

F2 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Plan. The vesting commencement date of the option is the grant date. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of the option's vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-144995 · tm2134192-2_4seq1.xml · nonDerivative · entry 1

Burek Julie · CIK 0001894915 · VP, Finance

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,522

F1 · shares: Consists of shares of common stock issuable under restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "2015 Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is January 1, 2022. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-078229 · tm2119100-1_4seq1.xml · derivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director · Interim CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2031-06-07

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over one year with 1/12th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/12th of the shares of common stock underlying the option vesting at the end of each successive one-month period, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077074 · tm2118780d3_4seq1.xml · derivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077081 · tm2118780d7_4seq1.xml · derivative · entry 1

Vitale Nancy · CIK 0001823262 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077079 · tm2118780d6_4seq1.xml · derivative · entry 1

PAUL STEVEN M · CIK 0001237564 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077078 · tm2118780-5_4seq1.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077072 · tm2118780d2_4seq1.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077076 · tm2118780d4_4seq1.xml · derivative · entry 1

Higgins Michael J · CIK 0001478521 · Director · Interim President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,000

Underlying: Common Stock · 115,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over one year with 1/12th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/12th of the shares of common stock underlying the option vesting at the end of each successive one-month period, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-077066 · tm2118780-1_4seq1.xml · derivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director · Interim CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2031-06-03

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. The option vests over one year with 1/12th of the shares of common stock underlying the option vesting upon the one-month anniversary of the Vesting Commencement Date and an additional 1/12th of the shares of common stock underlying the option vesting at the end of each successive one-month period, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-071822 · tm2117475-1_4seq1.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 120,509

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on May 20, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

SEC source: 0001104659-21-047689 · tm2112333-1_4seq1.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,056

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

SEC source: 0001104659-21-040308 · tm2110581-4_4seq1.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 124,025

F1 · shares: Consists of shares of common stock issuable under an aggregate of 35,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-040307 · tm2110581-3_4seq1.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,348

F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-040304 · tm2110581-2_4seq1.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 322,375

F1 · shares: Consists of shares of common stock issuable under an aggregate of 80,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-040302 · tm2110581-1_4seq1.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,894

F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, March 19, 2021. The RSU award vests over two years, with 1/2 of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and the remainder of the shares of common stock underlying the RSU award vesting on the two-year anniversary of such vesting commencement date, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025278 · tm217191-4_4seq1.xml · derivative · entry 2

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 189,000

Underlying: Common Stock · 189,000 shares

Expires 2031-02-16

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025278 · tm217191-4_4seq1.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 242,375

F1 · shares: Consists of shares of common stock issuable under an aggregate of 94,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025276 · tm217191-3_4seq1.xml · derivative · entry 2

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,000

Underlying: Common Stock · 72,000 shares

Expires 2031-02-16

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025276 · tm217191-3_4seq1.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,025

F1 · shares: Consists of shares of common stock issuable under an aggregate of 36,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025273 · tm217191-2_4seq1.xml · derivative · entry 2

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2031-02-16

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025273 · tm217191-2_4seq1.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,348

F1 · shares: Consists of shares of common stock issuable under an aggregate of 34,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025269 · tm217191-1_4seq1.xml · derivative · entry 2

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,000

Underlying: Common Stock · 68,000 shares

Expires 2031-02-16

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 16, 2021. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-025269 · tm217191-1_4seq1.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,894

F1 · shares: Consists of shares of common stock issuable under an aggregate of 34,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 16, 2021. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-21-023993 · tm216891-4_4seq1.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 148,375

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-023939 · tm216891-2_4seq1.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,348

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-023961 · tm216891-3_4seq1.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,894

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-023923 · tm216891-1_4seq1.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,025

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 10, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.65, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-004321 · tm213214-2_4seq1.xml · nonDerivative · entry 1

Turenne Andre · CIK 0001747102 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,352

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-21-004320 · tm213214-1_4seq1.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,080

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on January 11, 2021. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.45 to $8.75, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-105669 · a4.xml · derivative · entry 1

Vitale Nancy · CIK 0001823262 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2030-09-15

F1 · derivative.exercise_date: The stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date of the option is the grant date. The shares of common stock underlying the option are scheduled to vest in equal quarterly installments through September 15, 2024, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070318 · a4.xml · derivative · entry 1

LEVIN MARK J · CIK 0001180428 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070330 · a4.xml · derivative · entry 1

PIERCE GLENN · CIK 0001256964 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070329 · a4.xml · derivative · entry 1

Higgins Michael J · CIK 0001478521 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070327 · a4.xml · derivative · entry 1

GERAGHTY JAMES A · CIK 0001239746 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070328 · a4.xml · derivative · entry 1

Hyman Steven · CIK 0001656506 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070323 · a4.xml · derivative · entry 1

PAUL STEVEN M · CIK 0001237564 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-070326 · a4.xml · derivative · entry 1

DIXON WENDY L · CIK 0001202283 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2030-06-04

F1 · derivative.exercise_date: This stock option was issued pursuant to the 2015 Stock Option and Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the one-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-065492 · a4.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,500

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on May 20, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

SEC source: 0001104659-20-044247 · a4.xml · nonDerivative · entry 1

Hesslein Robert W. · CIK 0001585018 · Senior VP & General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,534

F1 · shares: Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on April 1, 2020. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.10 to $8.52, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

SEC source: 0001104659-20-019453 · a4.xml · derivative · entry 2

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-02-10

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-019453 · a4.xml · nonDerivative · entry 1

Khwaja Omar · CIK 0001776393 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

F1 · shares: Consists of shares of common stock issuable under an aggregate of 30,000 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-019457 · a4.xml · derivative · entry 2

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-02-10

F2 · derivative.exercise_date: This stock option was issued pursuant to the Plan. The vesting commencement date of the option is the grant date, February 10, 2020. The option vests over four years, with 1/48th of the shares of common stock underlying the option vesting upon the one-month anniversary of such vesting commencement date and an additional 1/48th of the shares of common stock underlying the option vesting at the end of each successive one-month period thereafter, subject to the Reporting Person's continued service.

SEC source: 0001104659-20-019457 · a4.xml · nonDerivative · entry 1

Dorval Allison · CIK 0001625110 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,022

F1 · shares: Consists of shares of common stock issuable under an aggregate of 27,500 restricted stock units ("RSUs") awarded to the Reporting Person pursuant to the Voyager Therapeutics, Inc. 2015 Stock Option and Incentive Plan (the "Plan"). Each RSU represents the right to receive one share of common stock upon vesting. The vesting commencement date of the RSU award is the grant date, February 10, 2020. The RSU award vests over three years, with 1/3rd of the shares of common stock underlying the RSU award vesting on the one-year anniversary of such vesting commencement date and an additional 1/3rd of the shares of common stock underlying the RSU award vesting at the end of each successive one-year period thereafter, subject to the Reporting Person's continued service.